Loading patent…
AssigneeNational Institutes of Biomedical Innovation, Health and Nutrition
InventorsKen Ishii, Etsushi Kuroda, Burcu Temizoz
Estimating the term…
The present invention provides the induction of novel Th1 response, the induction of cytotoxic T cells and anti-cancer/anti-allergic activity techniques. Provided is a combination of a CpG oligonucleotide and an STING agonist. Also provided is a composition which contains an STING agonist, can be used as a type-I adjuvant, and is characterized in that the STING agonist is administered together with a CpG oligonucleotide. Further provided is an anti-cancer agent comprising a CpG oligonucleotide and is characterized in that the CpG oligonucleotide is administered together with an STING agonist. Still further provided is a composition which contains a CpG oligonucleotide and can be used for reducing or eliminating the IgE-inducing activity of an STING agonist.
A combination of a CpG oligonucleotide and a STING agonist.
-3. (canceled)
(canceled)
The method of claim 26, wherein the cancer is selected from lymphoma and melanoma.
The method of claim 23, wherein the treatment or prevention is achieved by reducing or eliminating a type II immune response and expressing or enhancing a type I immune response.
The method of claim 23 wherein the treatment or prevention is achieved by inducing interferon γ (IFN-γ).
The method of claim 23 wherein the treatment or prevention is achieved by a vaccine adjuvant.
-22. (canceled)
A method of treating or providing prevention to a subject, comprising administering an effective amount of a CpG oligonucleotide and an effective amount of a STING agonist to the subject.
A method of exerting a type I adjuvant effect of a STING agonist, comprising administering the STING agonist in conjunction with a CpG oligonucleotide.
A method of enhancing action of a type I adjuvant of a CpG oligonucleotide, comprising administering the CpG oligonucleotide in conjunction with a STING agonist.
(canceled)
Dependencies are inferred from the claim text.